Clinical trial
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Prospective, Single Arm, Unblinded Pre-market Clinical Study to Evaluate the Safety and Effectiveness of the Sphere-360 Catheter and Affera Mapping and Ablation System for Treating Paroxysmal Atrial Fibrillation (PAF)
NCT07308847 is registered in ClinicalTrials.gov with Medtronic Cardiac Ablation Solutions as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Prospective, Single Arm, Unblinded Pre-market Clinical Study to Evaluate the Safety and Effectiveness of the Sphere-360 Catheter and Affera Mapping and Ablation System for Treating Paroxysmal Atrial Fibrillation (PAF)
- Lead sponsor
- Medtronic Cardiac Ablation Solutions
- Phase
- Not applicable
- Overall status
- Active, not recruiting
- Start date
- January 15, 2026
- Completion date
- September 30, 2027
- Enrollment
- 300 (actual)
- Sites
- 24
Conditions
As the registry lists them; a condition with its own page is linked.
paroxysmal af